Target Addition – general. Subject to the further provisions of this Section 2.5, Merck shall have the right, at any time prior to […***…], to expand the research activities to be undertaken by the Parties under the Research Programs so as to include, among other things, […***…]; provided that the total number of Target Combinations that Merck may add under this Section 2.5.4 is no more than […***…] (and for the purposes of this Section 2.5.4 and Section 5.2, a single Immuno-oncology Target will also be deemed to be a single “Added Target Combination”). Each such addition of an Immuno-oncology Target Combination is referred to herein as a “Target Addition”, and the Immuno-oncology Target Combination that, as a result of the Target Addition, is added to the Research Programs is referred to herein as an “Added Target Combination”. Section 2.12.4 shall apply.
Appears in 5 contracts
Samples: Research Collaboration and Exclusive License Agreement (Ablynx NV), Research Collaboration and Exclusive License Agreement (Ablynx NV), Research Collaboration and Exclusive License Agreement (Ablynx NV)
